Showing 2701-2710 of 3872 results for "".
- Tell-All Tribune Explores Most Important Topics in Aesthetic Medicinehttps://modernaesthetics.com/news/tell-all-tribune-explores-most-important-topics-in-aesthetic-medicine/2473565/The inaugural Tell-All Tribune: An Aesthetic Think Tank was held in Fort Lauderdale, Florida, from April 18-20, and could perhaps be summed up in six words from course director Shino Bay Aguilera, DO: “What we do goes beyond vanity." Along with fellow course directors Michell
- Zubritsky Joins Detergent Brand as Chief Dermatology Advisorhttps://modernaesthetics.com/news/zubritsky-joins-detergent-brand-as-chief-dermatology-advisor/2473562/Board-certified dermatologist and popular social media influencer Lindsey Zubritsky, MD, FAAD, has joined all® free clear as
- Highlights From IMCAS World Congress 2024: 25 years at the Forefront of Medical Aesthetics and Countinghttps://modernaesthetics.com/news/highlights-from-imcas-world-congress-2024-25-years-at-the-forefront-of-medical-aesthetics-and-counting-1/2473561/As a veteran of the International Master Course on Aging Science (IMCAS) for over two decades, IMCAS 2024 was the largest congress to date with over 18,000 attendees in the Palais des Congres. Located in central Paris, we had to navigate a construction zone as workmen were busy getting the city r
- Nordic Pharma Welcomes John P. Fezza, MD, to Medical Advisory Boardhttps://modernaesthetics.com/news/nordic-pharma-welcomes-john-fezza-md-to-medical-advisory-board/2473554/Nordic Pharma, Inc., has announced the appointment of renowned oculoplastic surgeon Dr. John P. Fezza, MD, to its U.S. Medical Advisory Board (MAB), according to a press release. The appointment comes as Nordic Pharma prepares to introduce LACRIFILL® Canalicular Gel, a groundb
- FDA Approves Juvederm Voluma XC for Temple Hollowinghttps://modernaesthetics.com/news/fda-approves-juvederm-voluma-xc-for-temple-hollowing/2473553/Allergan Aesthetics has received FDA approval of Juvederm Voluma XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.[1] The injection is the first and only hyaluronic acid (HA) dermal filler to receive FDA approval
- Cutera Launches AviClear for the Treatment of Acne in UK, Europe and Australiahttps://modernaesthetics.com/news/cutera-launches-aviclear-for-the-treatment-of-acne-in-uk-europe-and-australia/2473548/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- Demand Up, Fees Downhttps://modernaesthetics.com/news/demand-up-fees-down/2473541/The latest study from The American Society of Plas
- Genese Labs Introduces the RG60 Body Fillerhttps://modernaesthetics.com/news/genese-labs-introduces-the-rg60-body-filler/2473539/Genese Labs France is rolling out the RG60 Body Filler, an injectable composed of a 24mg/ml cross-linked hyaluronic acid concentration. RG60 can be used in the face and body including the buttocks. Free from lidocaine, RG60 ensures a safer experience
- Allergan Aesthetics and The Black Beauty Club Partner to Foster Diversity in Aestheticshttps://modernaesthetics.com/news/allergan-aesthetics-x-the-black-beauty-club-partner-to-advance-diversity-in-aesthetics/2473531/Allergan Aesthetics joined forces with the Black Beauty Club for a consumer initiative to spark open dialogue and empower Black individuals to embrace their unique beauty and make informed decisions about their aesthetic care. The event, which took place in Atlanta on Novembe
- Exosome Update: ELEVAI Labs Announces Pricing of $6,000,000 IPOhttps://modernaesthetics.com/news/exosome-update-elevai-labs-announces-pricing-of-6000000-ipo/2473530/Elevai Labs, Inc. announced the pricing of its initial public offering. The Offering consists of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting discounts and o